ZA201807992B - Method of treating liver fibrosis - Google Patents
Method of treating liver fibrosisInfo
- Publication number
- ZA201807992B ZA201807992B ZA2018/07992A ZA201807992A ZA201807992B ZA 201807992 B ZA201807992 B ZA 201807992B ZA 2018/07992 A ZA2018/07992 A ZA 2018/07992A ZA 201807992 A ZA201807992 A ZA 201807992A ZA 201807992 B ZA201807992 B ZA 201807992B
- Authority
- ZA
- South Africa
- Prior art keywords
- liver fibrosis
- treating liver
- fibrosis
- treating
- t2dm
- Prior art date
Links
- 208000019425 cirrhosis of liver Diseases 0.000 title abstract 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 4
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 abstract 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010019668 Hepatic fibrosis Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662345086P | 2016-06-03 | 2016-06-03 | |
| PCT/US2017/035628 WO2017210526A1 (en) | 2016-06-03 | 2017-06-02 | Method of treating liver fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201807992B true ZA201807992B (en) | 2023-10-25 |
Family
ID=60479090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2018/07992A ZA201807992B (en) | 2016-06-03 | 2018-11-26 | Method of treating liver fibrosis |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10682344B2 (enExample) |
| EP (1) | EP3463350B1 (enExample) |
| JP (2) | JP2019517523A (enExample) |
| KR (1) | KR102444366B1 (enExample) |
| CN (2) | CN115154467B (enExample) |
| AU (1) | AU2017274521B2 (enExample) |
| BR (1) | BR112018074452A2 (enExample) |
| CA (1) | CA3025671C (enExample) |
| ES (1) | ES2966111T3 (enExample) |
| IL (1) | IL263245B (enExample) |
| MX (1) | MX387070B (enExample) |
| RU (1) | RU2740902C2 (enExample) |
| SG (2) | SG11201810602YA (enExample) |
| WO (1) | WO2017210526A1 (enExample) |
| ZA (1) | ZA201807992B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| US11571431B2 (en) | 2013-12-04 | 2023-02-07 | Galmed Research And Development Ltd | Aramchol salts |
| IL243707A0 (en) | 2016-01-20 | 2016-05-01 | Galmed Res And Dev Ltd | Treatment to regulate the microbiota in the intestine |
| SG11201810602YA (en) * | 2016-06-03 | 2018-12-28 | Chemocentryx Inc | Method of treating liver fibrosis |
| JP6678779B2 (ja) | 2016-06-13 | 2020-04-08 | ギリアード サイエンシーズ， インコーポレイテッド | Ｆｘｒ（ｎｒ１ｈ４）調節化合物 |
| CA3252823A1 (en) | 2016-06-13 | 2025-02-25 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
| US11197870B2 (en) | 2016-11-10 | 2021-12-14 | Galmed Research And Development Ltd | Treatment for hepatic fibrosis |
| KR20190083659A (ko) * | 2016-11-10 | 2019-07-12 | 갈메드 리서치 앤드 디벨롭먼트 리미티드 | 섬유증에 대한 치료 |
| PT4122464T (pt) | 2017-03-28 | 2024-06-27 | Gilead Sciences Inc | Combinações terapêuticas para o tratamento de doenças do fígado |
| KR102600115B1 (ko) | 2017-06-05 | 2023-11-09 | 바이킹 테라퓨틱스 인코포레이티드 | 섬유증 치료를 위한 조성물 |
| CN111406051A (zh) | 2017-09-03 | 2020-07-10 | 安吉昂生物医药公司 | 作为rho相关卷曲螺旋激酶(rock)抑制剂的乙烯基杂环 |
| US11292785B2 (en) | 2018-02-02 | 2022-04-05 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Nitrogen-containing benzoheterocycle compound comprising carboxylic acid group, preparation method and use thereof |
| WO2019183004A1 (en) | 2018-03-22 | 2019-09-26 | Viking Therapeutics, Inc. | Crystalline forms and methods of producing crystalline forms of a compound |
| CN113683597A (zh) * | 2018-06-12 | 2021-11-23 | 四川海思科制药有限公司 | 甲状腺激素受体激动剂及其用途 |
| CN112996490A (zh) * | 2018-08-14 | 2021-06-18 | 阿沃林特有限公司 | 治疗原发性硬化性胆管炎的方法 |
| GB201813678D0 (en) * | 2018-08-22 | 2018-10-03 | Keybioscience Ag | Acylated calcitonin mimetics |
| US12102646B2 (en) * | 2018-12-05 | 2024-10-01 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| SG11202107434PA (en) | 2019-01-15 | 2021-08-30 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| CN118388473A (zh) | 2019-02-19 | 2024-07-26 | 吉利德科学公司 | Fxr激动剂的固体形式 |
| WO2020181163A1 (en) * | 2019-03-06 | 2020-09-10 | Tobira Therapeutics, Inc. | Lipid-based formulation of cenicriviroc |
| PE20220255A1 (es) | 2019-05-08 | 2022-02-16 | Aligos Therapeutics Inc | Moduladores de thr y metodos de uso de estos |
| CN114207143A (zh) * | 2019-07-30 | 2022-03-18 | Ko生物技术有限公司 | 预测或诊断非酒精性脂肪肝病的试剂盒及诊断非酒精性脂肪肝病的方法 |
| JP7499841B2 (ja) | 2019-07-30 | 2024-06-14 | コバイオラブス，インコーポレーテッド | 非アルコール性脂肪性肝疾患の予測若しくは診断用キット、および診断方法 |
| WO2021102251A1 (en) * | 2019-11-22 | 2021-05-27 | Avolynt | Use of sglt2 inhibitors to treat primary billiary cholangitis |
| CN113274368B (zh) * | 2020-02-20 | 2023-08-22 | 甘莱制药有限公司 | 一种用于治疗脂肪性肝炎的药物组合物及其制备方法 |
| US11478533B2 (en) * | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| MX2023003401A (es) * | 2020-10-08 | 2023-04-25 | Curome Biosciences Co Ltd | Composicion farmaceutica para prevenir o tratar enfermedad hepatica colestasica, que contiene beta-lapachona como ingrediente activo. |
| CN120899882A (zh) * | 2025-06-16 | 2025-11-07 | 中国疾病预防控制中心寄生虫病预防控制所(国家热带病研究中心) | Klb蛋白在制备治疗血吸虫感染的药物上的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005118578A1 (en) * | 2004-05-26 | 2005-12-15 | Janssen Pharmaceutica N.V. | Mercaptoimidazoles as ccr2 receptor antagonists |
| US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| EP2474532A1 (en) | 2005-01-14 | 2012-07-11 | ChemoCentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| US8067457B2 (en) * | 2005-11-01 | 2011-11-29 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of CCR2 |
| US20070219245A1 (en) * | 2006-03-14 | 2007-09-20 | Cuifen Hou | Method of use for substituted dipiperidine ccr2 antagonists |
| US8519135B2 (en) | 2006-07-14 | 2013-08-27 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2/CCR9 |
| US7683176B2 (en) * | 2006-07-14 | 2010-03-23 | Chemocentryx, Inc. | Triazolyl pyridyl benzenesulfonamides |
| US7776877B2 (en) * | 2007-06-22 | 2010-08-17 | Chemocentryx, Inc. | N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides |
| ATE548039T1 (de) * | 2007-07-12 | 2012-03-15 | Chemocentryx Inc | Kondensierte heteroarylpyridyl- und phenylbenzensulfonamide als ccr2-modulatoren zur behandlung von entzündungen |
| PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
| MX2011001911A (es) | 2008-08-18 | 2011-07-04 | Pfizer | Anticuerpos para ccr2. |
| WO2011073154A1 (en) * | 2009-12-17 | 2011-06-23 | Boehringer Ingelheim International Gmbh | New ccr2 receptor antagonists and uses thereof |
| WO2012114223A1 (en) * | 2011-02-25 | 2012-08-30 | Pfizer Limited | A method of treating liver fibrosis |
| US8658787B2 (en) * | 2011-09-16 | 2014-02-25 | Galectin Therapeutics Inc. | Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease |
| JP2015516404A (ja) * | 2012-05-09 | 2015-06-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 代謝疾患の処置のための合剤 |
| TWI696462B (zh) * | 2013-07-10 | 2020-06-21 | 日商興和股份有限公司 | 非酒精性脂肪性肝疾病治療劑 |
| EP3191100A4 (en) * | 2014-09-12 | 2018-05-30 | Tobira Therapeutics, Inc. | Cenicriviroc combination therapy for the treatment of fibrosis |
| SG11201810602YA (en) * | 2016-06-03 | 2018-12-28 | Chemocentryx Inc | Method of treating liver fibrosis |
-
2017
- 2017-06-02 SG SG11201810602YA patent/SG11201810602YA/en unknown
- 2017-06-02 RU RU2018145459A patent/RU2740902C2/ru active
- 2017-06-02 BR BR112018074452-2A patent/BR112018074452A2/pt not_active Application Discontinuation
- 2017-06-02 ES ES17807548T patent/ES2966111T3/es active Active
- 2017-06-02 CN CN202210819034.8A patent/CN115154467B/zh active Active
- 2017-06-02 US US15/612,124 patent/US10682344B2/en active Active
- 2017-06-02 JP JP2018563453A patent/JP2019517523A/ja not_active Withdrawn
- 2017-06-02 WO PCT/US2017/035628 patent/WO2017210526A1/en not_active Ceased
- 2017-06-02 EP EP17807548.7A patent/EP3463350B1/en active Active
- 2017-06-02 SG SG10202012080UA patent/SG10202012080UA/en unknown
- 2017-06-02 AU AU2017274521A patent/AU2017274521B2/en active Active
- 2017-06-02 CN CN201780048523.5A patent/CN109475537A/zh active Pending
- 2017-06-02 KR KR1020187037797A patent/KR102444366B1/ko active Active
- 2017-06-02 CA CA3025671A patent/CA3025671C/en active Active
- 2017-06-02 MX MX2018014743A patent/MX387070B/es unknown
-
2018
- 2018-11-25 IL IL263245A patent/IL263245B/en unknown
- 2018-11-26 ZA ZA2018/07992A patent/ZA201807992B/en unknown
-
2020
- 2020-05-06 US US16/867,956 patent/US11357760B2/en active Active
-
2022
- 2022-05-11 US US17/662,979 patent/US20220313668A1/en not_active Abandoned
- 2022-11-30 JP JP2022191906A patent/JP7431931B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201807992B (en) | Method of treating liver fibrosis | |
| MX2025003745A (es) | Analogos de incretina y sus usos | |
| MY199143A (en) | Incretin analogs and uses thereof | |
| PH12017502359A1 (en) | Glucagon and glp-1 co-agonist compounds | |
| MX2018009170A (es) | Biomarcadores de la enfermedad del higado graso no alcoholico (nafld) y esteatohepatitis no alcoholica (nash) y usos de estos. | |
| AR118965A1 (es) | Combinaciones para el tratamiento de nash / nafld y enfermedades relacionadas | |
| SA521430550B1 (ar) | Glp-1r عوامل مساعدة لـ واستخداماتها | |
| MX360140B (es) | Biomarcadores de la enfermedad del higado graso no alcoholico (nafld) y la esteatohepatitis no alcoholica (nash) y usos de estos. | |
| MY188739A (en) | A method to produce a wear resistant layer with different gloss levels | |
| MX382408B (es) | Coagonistas de los receptores de glucagón y de glp-1. | |
| AR104844A1 (es) | Método para recubrimiento de un chupetín | |
| MX2019005533A (es) | Tratamiento de la fibrosis. | |
| WO2014106846A3 (en) | Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof | |
| EP3804153A4 (en) | SERDES WITH JITTER INJECTION SELF-TENSION MECHANISM | |
| MX369571B (es) | Composicion para prevenir o tratar enfermedades del higado graso. | |
| IL276935A (en) | A therapeutic agent for hepatocellular carcinoma | |
| EP4596044A3 (en) | Combination therapy of gpr119 agonists and dpp-4 inhibitors | |
| EP4234536A3 (en) | Amino-aryl-benzamide compounds and methods of use thereof | |
| CY1124611T1 (el) | Θεραπειες μη-αλκοολικης στεατοηπατιτιδας (nash) | |
| EA202091461A1 (ru) | Пептиды для лечения и профилактики неалкогольной жировой болезни печени и фиброза | |
| Fortington et al. | Same, same but different… injury and safety promotion in rugby | |
| Tatsuno et al. | A case study about the sweat acceleration by the foot bath | |
| MATSUMIYA | Urbanization of Ulaanbaatar with reference to Ger Areas | |
| Jiaxu | Influence of the Traditional Chinese Culture on the Expansion of Buddhism in China | |
| TWD170224S (zh) | 門板(二) |